ADHD Treatment Options Available in the UK In the UK, NICE guidelines (NG87) provide comprehensive recommendations for the diagnosis and management of ADHD in children, young people, and adults
In June, Eli Lilly has announced Phase II results of its SYNERGY-NASH trial in which 54.9% of patients on its dual GLP-1/GIP receptor agonist tirzepatide 5 mg, 51.3% of patients on tirzepatide 10 mg and 51% of patients on tirzepatide 15 mg saw their fibrosis decreaseby at least one stage without their metabolic dysfunction-associated steatohepatitis (MASH) worsening
Widely studied in experimental models, it shows potential for skeletal muscle hypertrophy, cognitive function, regenerative medicine, and sports performance research
Weeks 5 to 16 (titration through 1.7 mg): Expect peak nausea
Some researchers find that their response to tirzepatide diminishes after months of use, even at the maximum 15 mg dose
You might be wondering, Does what I eat while on GLP-1s actually matter? The short answer is yes, but not for the reasons you might think